Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Hugh Cleland

Blumont Capital
http://www.blumontcapital.com/home.html

Image: Hugh Cleland

Hugh C. Cleland is an executive vice-president and portfolio manager at BluMont Capital Corp., based in Toronto, Canada. BluMont Capital acquired Northern Rivers Capital Management, which was founded by Cleland in May 2001, in January 2010. Cleland currently manages two funds for BluMont: the BluMont Northern Rivers Innovation RSP Fund (available on FundSERV), and the BluMont Innovation PE Strategy Fund I, which takes a private equity approach to the management of publicly traded small- and micro-cap technology and healthcare stocks. Cleland worked at Interward Capital Corp. from 1998 to 2001, originally as an analyst and later as associate portfolio manager specializing in technology equities. In 1997–1998 he was research associate to the senior telecom services analyst at Midland Walwyn Inc. Cleland earned a bachelor's degree with honors (1997) from Harvard University, and earned his CFA designation in 2001.



Recent Interviews

Applying the Venture Capital Model to Public Companies: Hugh Cleland (11/15/12) Hugh Cleland has been testing his theory that life sciences companies can be had cheaper as stocks than as private venture capital investments—and that theory has been working out for him quite well over the past two years. In this interview with The Life Sciences Report, Cleland, portfolio manager and executive vice president at Toronto-based BluMont Capital, talks about his best small- and micro-cap ideas and also shares the "core/farm team" approach that he takes in his smaller, more conventionally structured fund.

Think Long Term and Win Big with Small Biotechs: Hugh Cleland (8/9/12) BluMont Capital Portfolio Manager Hugh Cleland has taken a venture capital and private equity approach to investing in public companies, some of which have penny-stock market caps in the $5–15 million range. The idea is to invest in small- and micro-cap stocks without facing redemption risk, and to employ a hands-on approach when helping innovative companies create and realize value over the long term. In this way time becomes the friend—not the enemy—of companies looking for scarce capital in a risk-averse world. In this exclusive interview with The Life Sciences Report, Cleland shares the names of a handful of small companies that could return tenfold or greater multiples to investors.

Recent Quotes

"The Angelo VMS preliminary data has been excellent, and that suggests FDA approval is likely for VPT." (11/15/12) VentriPoint Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"Financing will give investors even more confidence that LPTN will have the capital it needs." (11/15/12) Lpath Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"CTH could very well be worth more than CA$200M in three to five years." (11/15/12) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"I consider VPT to be a low-risk/high-reward opportunity." (8/9/12) VentriPoint Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"If CTH can raise the money it needs, I expect it will create shareholder value in the $100–300M range within two to three years." (8/9/12) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Hugh Cleland More >